Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  +1.30p +6.28% 22.00p 574,464 15:51:37
Bid Price Offer Price High Price Low Price Open Price
21.40p 22.60p 22.80p 20.70p 20.70p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.6 -4.2 - 20.52

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Share Charts

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart

Intraday Evgen Pharma Chart

Intraday Evgen Pharma Chart

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date Time Title Posts
25/5/201816:33Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer443
26/6/201707:38Evgen Pharma Plc Investor Presentation-
13/6/201709:45Evgen Pharma Interview-
29/11/201608:27Evgen Pharma (EVG) chief executive Stephen Franklin39

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-05-25 15:22:1222.601,743393.92O
2018-05-25 14:54:2821.6020,1674,356.07O
2018-05-25 14:54:1721.601,417306.07O
2018-05-25 14:54:0822.563,297743.94O
2018-05-25 14:50:5222.0011,0002,420.00O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

Evgen Pharma Daily Update: Evgen Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 20.70p.
Evgen Pharma has a 4 week average price of 17.25p and a 12 week average price of 12.25p.
The 1 year high share price is 29.38p while the 1 year low share price is currently 12p.
There are currently 93,276,858 shares in issue and the average daily traded volume is 322,720 shares. The market capitalisation of Evgen Pharma is £20,520,908.76.
nico115: Nobby Let me know if and when you have bought anyI think risk reward is good Not sure I will be in this for phase 2 but am hoping for a good read out and a doubling in the share price We have rallied a few times on a lot less than a good readout Tgt price 37p
bernymadoff: Only idiots look at the rise and fall of a share price to determine whether they should invest and at what price. It wasn't long ago that institutions were paying 37p on IPO to get exposure to the drugs EVG are testing. Since then many of them have continued to buy and they currently hold 55% or so of the whole company. Institutional investment is one of the major ingredients I look for when deciding to invest anywhere. It gives you a level of confidence knowing that experts have evaluated the company to a degree that lay people could not achieve. Big plus there. Then there is the performance of the company. To date EVG have not put a foot wrong and all their drug trials have exceeded market expectations. Yet the market has not assigned any value to the progress the company has made since IPO in October 2015. Like many other pre-revenue AIM companies with great potential it has been at the mercy of the spivs in the city who have manipulated the share price down so that they can screw the company in the knowledge that it is dependent on placings to see it through to commercialisation. There is a wealth of information out there showing just how disconnected the share price is to the actual potential of EVG. For me that's where the opportunity lies. The greater the disconnect the greater the correction (in fact in these cases the correction often overshoots to the overvalued side). The other big thing the company has going for it is that it is funded through to the end of the year by which point it may well have landed a licensing or JV deal if the results due this quarter and then again at the end of the year are any good. Certainly the CEO has been dropping hints to that effect in recent rns'. You can choose to play the swings or you can hold for the big prize that the evidence suggests is now within grasp.
timbo003: As long as it's good news for the company that's all that matters Most certainly agreed, but with the caveat that if the company has a short term funding requirement and they are relying on an equity based raise to meet that requirement, then it is important (for all concerned) that the the share price accurately reflects the company's prospects. Fortunately Evgen are no longer in a situation where they need to raise funds in the short term
nico115: Maybe some delayed ones and maybe they just ignoring the ramper now Patents never give a boost to the share priceBerney stay real mate
nico115: Berney Once you lose respect you lose your marbles While you were ranting that this news was great the shares just tumbled 15pctMore respect Plse!!I like evg a lot and hold a lot of shares but unlike you Bernay I won't ramp daily to get share price up..You have just lost the 22p buyers 18pct..they could've bought cheaper if they didn't have to read your Cr p
bernymadoff: Share price is strengthening by the day. I'm happier seeing solid sustainable rises like this than spikes. I would expect this pattern to continue into news and if the interim readouts are good it could easily be blue sky.
timbo003: Worth noting that in December Beaufort held >2% of the shares (see link to December Hardman note in the header). I don't know what they hold now, as we haven't had a Hardman update since, but could the unwinding of that position have been a major cause of the share price weakness earlier this year?
pdt: It will be interesting to see where the share price goes next week given last weeks moves. I am a "buy and hold" investor and I am hopeless at getting the timing right. However, I do know what news is expected over the next 12 months; 1. Interim read of the P2 Breast Cancer trial in the next 2 months. 2. Full readout around Dec 2018 (market size for indication: $5 billion) 3. Full readout of SAH P2 trial expected around Q1 2019 orphan status (market size $1 billion) 4. News on the Charity funded research by Christies Manchester in triple negative breast cancer and SFX-01 5. Kings London may have results on Stroke research with SFX-01 and may announce trial early 2019 6. Possible licencing after Interim read suggested for by paid research note 7. Franklin was in the US Orphan Indication conference last week and had a slot in the "pitch and partner" section so may have licencing in SAH within 12 months or sooner 8. Autism and SFX-01 research with St Thomas's possible in next 12 months 9. Brain Cancer and SFX-01 research with a partner in the next 12 months possible 10. Huge amount of independent research to be published over the next 12 month in Sulforaphane ( perhaps 300 papers at the current rate?) I am sure I have missed some expected news. At a market cap of £16m , current price of 18p and price target of 113p by Northlands it is an interesting time. Good luck to those hoping for short term ups and downs! I have no idea.
l0ngterm: PDT: thanks I will have a read through. As for IMM and comparisons, I don't think it is a fair comparison, due to the below.A) company approach is focused on the business, and that will take care of the share price eventually.B) the science has been researched and potential identified from multiple independent sources.D) the papers published are from multiple different sources and specialists. C) the compassionate use program has been running for a while, with one, possible more patients taking the drug for over a year. So supporting data etc. Held in advance.d) the companies approach is to partner as opposed to run phase III. So the trial design should be a lot more robust.All the above are pretty much lessons learned from where IMM dropped the ball, or that investment for me. Still trials are a risk, but ticking a lot of boxes here.Hence happy to buy.
timbo003: There doesn't seem to be any material event behind the recent rise, so presumably the reason is just another Pump and Dump. However, if the share price ends up higher than where it started , it will have served a useful purpose. I suspect the company will want to find a bit of cash from somewhere before they get the first readout from the two ongoing clinical studies and according to the last Hardman report they will be running on empty by March next year. If the cash is to come from an equity based fund raise (which seems likely), then the higher the price the better as far as I am concerned.
Evgen Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180526 00:24:35